Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • myelodysplastic syndrome

    - PMLiVE

    Gilead’s Yescarta shows benefits for patients with large B-cell lymphoma

    This is the most common type of non-Hodgkin lymphoma worldwide

    - PMLiVE

    Gilead reports Trodelvy breast cancer trial missed primary survival endpoint

    The drug treatment is being evaluated in several ongoing phase 3 trials

    - PMLiVE

    FDA unveils new voucher programme to accelerate drug review process

    The programme is designed to reduce the review time for companies supporting US national interests

    - PMLiVE

    Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer

    Triple-negative breast cancer accounts for approximately 15% of all cases of the disease

    - PMLiVE

    FDA approves Bavarian Nordic’s chikungunya vaccine for individuals aged from 12 years

    The mosquito-borne viral disease has been reported across many popular travel destinations

    - PMLiVE

    Roche’s Evrysdi tablet formulation granted FDA approval for spinal muscular atrophy

    The progressive neuromuscular disease affects approximately one in every 10,000 babies globally

    - PMLiVE

    FDA accepts updated protocol for Annovis’ phase 3 Alzheimer’s disease study

    The company hopes the revised protocol will accelerate the development timeline of buntanetap

    - PMLiVE

    Gilead’s seladelpar recommended by CHMP to treat primary biliary cholangitis

    The rare liver disease affects approximately 15 per 100,000 people in Europe

    - PMLiVE

    FDA approves BridgeBio Pharma’s Attruby to treat rare heart disease ATTR-CM

    Transthyretin amyloid cardiomyopathy affects up to 500,000 people worldwide

    - PMLiVE

    UCB’s Bimzelx granted FDA approval to treat hidradenitis suppurativa in adults

    The inflammatory skin disease affects approximately one in every 100 people in the US

    - PMLiVE

    ICR researchers identify potential treatment approach for acute myeloid leukaemia

    More than 3,100 people are diagnosed with the aggressive blood cancer in the UK every year

    - PMLiVE

    Novavax announces FDA clinical hold lift on phase 3 COVID-19/flu vaccine study

    The serious adverse event reported was found to be unrelated to the vaccine

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links